Compare ALVO & BBDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALVO | BBDC |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Financial Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 914.1M |
| IPO Year | 2021 | 2006 |
| Metric | ALVO | BBDC |
|---|---|---|
| Price | $6.16 | $8.63 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $6.80 | ★ $9.96 |
| AVG Volume (30 Days) | ★ 1.1M | 498.8K |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 12.05% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.52 |
| Revenue | N/A | N/A |
| Revenue This Year | $11.96 | N/A |
| Revenue Next Year | $17.65 | $2.05 |
| P/E Ratio | $18.20 | ★ $16.73 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.94 | $7.97 |
| 52 Week High | $9.05 | $9.54 |
| Indicator | ALVO | BBDC |
|---|---|---|
| Relative Strength Index (RSI) | 66.45 | 40.82 |
| Support Level | $3.15 | $8.22 |
| Resistance Level | N/A | $8.72 |
| Average True Range (ATR) | 0.34 | 0.16 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 75.77 | 11.65 |
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.
Barings BDC Inc operates as a closed-end, non-diversified investment company and has elected to be treated as a business development company. The company's investment objective is to generate current income by investing directly in privately held middle-market companies to help these companies fund acquisitions, growth, or refinancing. It employs fundamental credit analysis and targets investments in businesses with low levels of cyclicality and operating risk relative to other businesses in this market segment. The holding size of each position will generally be dependent upon a number of factors including total facility size, pricing and structure, and the number of other lenders in the facility.